Is Oveporexton legal in the United Kingdom?

An oral orexin receptor 2 agonist, not a peptide, approved by the FDA on 5 August 2026 for narcolepsy type 1 in adults. In two 12 week phase 3 trials totalling 273 people it lengthened time awake on the Maintenance of Wakefulness Test by 14 to 20 minutes against roughly no change on placebo; a majority of treated participants developed insomnia and urinary frequency.

51 daltons, not a peptide. It is on this site because it is the first approved drug that acts at the receptor for orexin-A, the wake-promoting peptide whose neurons are lost in narcolepsy type 1.

Mechanism: In people with narcolepsy type 1 the hypothalamic neurons that make orexin-A and orexin-B are lost, so both orexin peptides are deficient while their receptors remain. Oveporexton is a selective agonist at orexin receptor 2 (OX2R), the receptor most tied to maintaining wakefulness, and it restores signalling at that receptor without replacing the peptide.

Regulatory history: FDA approved 5 August 2026 (Orzeyful, NDA 220860, orphan designation, priority review) for narcolepsy type 1 in adults. Controlled substance schedule pending DEA review at the time of labelling.

Licenses medicines for the UK market. A compound without a marketing authorisation is an unlicensed medicine, which can only lawfully be supplied for human use through a prescriber under the specials scheme, not sold as a research product.

The classification above is the The Longevity Archive reading of Medicines and Healthcare products Regulatory Agency listings for Oveporexton at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.